- The FDA has authorized the first nonprescription test to detect Covid-19, influenza, and respiratory syncytial virus (RSV).
- The test, called the Labcorp Seasonal Respiratory Virus RT-PCR DTC Test, was developed by Laboratory Corp of America Holdings (NYSE:LH).
- It can be sold directly to consumers online or at retail.
- A person can self-collect a nasal swab sample at home and then send that sample to Labcorp for testing.
- According to Wall Street Journal, the test kit costs $169 but comes at no upfront cost to those who meet clinical guidelines and have insurance, a Labcorp spokesperson said.
- People without insurance would have to pay upfront when ordering a kit. A federal program meant to cover Covid-19 testing and treatment for those without an insurance ended in March after officials said it ran out of funds.
- Results are delivered through an online portal, with a follow-up from a healthcare provider if the outcome is positive or invalid.
- Price Action: LH shares closed at $242.38 on Monday.
- Photo by Mufid Majnun on Unsplash
Get all your news in one place.
100’s of premium titles.
One app.
Start reading
One app.
Get all your news in one place.
100’s of premium titles. One news app.
FDA Gives Nod To First Nonprescription COVID-19 Test That Also Detects Flu, RSV
Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member?
Sign in here
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member?
Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member?
Sign in here
Our Picks